Compound 566C80, 2-[trans-4-(4-chlorophenyl)cyclohexyl]-3-hydroxy-1,4-naphthoquinone, was studied for its in vitro and in vivo activities against Toxoplasma gondii. Replication within human foreskin fibroblasts of tachyzoites of seven different strains, five of them isolated from AIDS patients, was inhibited by concentrations as low as 4.8 x 10-9 M. In vivo, a dose of 100 mg/kg of body weight per day, administered by gavage for 10 days, protected 100% of mice against death due to infection with five different strains of T. gondii, including the highly virulent RH strain. A dose of 50 mg/kg/day protected at least 80% 'of mice infected with the same inoculum, and a dose as low as 9.3 mg/kg/day protected 40 to 60% of mice. Treatment with 50 mg/kg/day for 30 days completely eradicated parasites from mice infected with four of five strains of T. gondii. 566C80 was active in vitro against the cyst stage of T. gondii at concentrations of 50 to 100 ,ug/ml. In vivo activity against this form of T. gondii was examined in mice infected for 6 weeks with strain ME49 and then treated orally with 100 mg of 566C80 per kg per day for 8 weeks. Treated mice sacrfficed at 2-week intervals revealed a steady decline in the numbers of cysts in their brains compared with untreated controls. In addition, mortality as well as clinical signs of brain infection was absent from treated mice, whereas control mice had a high mortality rate and showed clinical signs of central nervous system infection. These results reveal remarkable in vitro and in vivo activities of 566C80 against T. gondii.
In addition to causing debilitating disease in congenitally infected infants and children, Toxoplasma gondii has emerged as a major opportunistic pathogen of immunocompromised individuals, particularly those infected with the human immunodeficiency virus (17, 18, 21) . The treatment of choice for toxoplasmosis has been the synergistic combination of pyrimethamine and a sulfonamide (3) . Prolonged treatment with pyrimethamine, a potent inhibitor of the enzyme dihydrofolate redyctase, may result in bone marrow depression, a side effect of particular importance in immunocompromised individuals (19) . When pyrimethamine is administered with a sulfonamide, the combination is associated with untoward effects in at least 60% of patients with AIDS, often leading to discontinuation of at least the sulfonamide component (12) . Moreover, because pyrimethamine is potentially teratogenic, its use during the early months of gestation is not recommended. Alternative drugs and treatment schemes have been shown to be effective in animal models of toxoplasmosis (1, 2, 4) , but their usefulness in treating the disease in humans and their efficacy compared with that of the pyrimethamine-sulfonamide combination remains to be confirmed in clinical trials. Thus, there is a critical need for the development and evaluation of new drugs or new drug combinations for the prevention and treatment of congenital toxoplasmosis, ocular toxoplasmosis in older children and adults, and toxoplasmosis in immunocompromised patients. Certain hydroxynaphthoquinones have previously been shown to have some activity in experimental toxoplasmosis, but they are not of sufficient promise to warrant development (11) . Hydroxynaphthoquinone 566C80 was originally synthesized at Wellcome Research ANTIMICROB. AGENTS CHEMOTHER. (14) . It was used either as a powder for in vitro experiments or as a suspension in 1% (vol/vol) Celacol for in vivo experiments.
In vitro activity. The in vitro activity of 566C80 was examined by using intracellular Six weeks after infection, the mice were treated by gavage with 100 mg of 566C80 per kg of body weight per day; treatment was continued for 8 weeks. Control mice were treated with diluent only. At 2-week intervals after the initiation of treatment, two or three mice were killed, the entire brains were removed, and the numbers of cysts in the brain suspensions were determined as described above.
Serum levels of 566C80 were determined by treating mice by gavage with 100 mg/kg/day for 4 days. Groups of three mice each were killed at 3, 6, 12, 24, and 48 h after the last treatment, and then the sera were collected, immediately frozen, and shipped in dry ice to the Wellcome Foundation, where levels of 566C80 in serum were determined by a technique based on gas chromatography. Results are expressed in micrograms per milliliter.
RESULTS
Activity against intracellular replication of T. gondii in vitro. The capacity of 566C80 to inhibit intracellular replication of T. gondii within HFF was different for the different strains of the parasite (Fig. 2 ). For tachyzoites of the RH strain, a concentration as high as 4.8 x 10-6 M was not sufficient to inhibit their replication completely ( Fig. 2A) . In contrast, intracellular replication of organisms of strains VEL and HART was completely inhibited by a concentration of 4.8 x 10-9 M ( Fig. 2B and C). For strains ME49 and POE, the lowest inhibitory concentration was 4.8 x 10-7 M ( Activity against isolated tissue cysts. Mice injected with cysts that had been incubated with medium alone or with medium containing 1 ,ug of 566C80 per ml (2.8 x 10-6 M) or 100 ,ug of clindamycin per ml all died between days 9 and 13 of the infection (Table 1) (Table 2) . Activity against different strains of T. gondii was determined by using an i.p. inoculum of 3 x 103 tachyzoites. Initiation of treatment was begun 24 h after infection, with 10, 20, or 50 mg/kg/day administered as a single daily dose for 30 days. As noted in the in vitro experiments, the results obtained in vivo also revealed a striking variation in the activity of 566C80 against the different strains of T. gondii (Fig. 4) . For example, 100% of mice infected with strain SO and treated with 10 mg/kg/day survived (Fig. 4A) Activity against T. gondii cysts in vivo. In spite of the wide mouse-to-mouse variation in the number of T. gondii cysts in the brain, treated mice had considerably fewer cysts in their brains than the controls (Fig. 5) . Moreover, the mortality rate among the control mice was continuous; by 13 weeks of infection, all were dead from the infection. No deaths occurred in the treated mice up to 14 weeks of infection (8 weeks of treatment), when the experiment was terminated. Levels of 566C80 in serum. Levels of 566C80 in serum are shown in Fig. 6 . At 3 and 24 h after the last dosing, the concentrations of 566C80 in the sera of the three mice killed at each time were 34.6 + 4.1 and 10.6 + 4.9 ,ug/ml, respectively (mean + standard deviation). There was considerable mouse-to-mouse variation.
DISCUSSION
The results above indicate that compound 566C80 has remarkable in vitro as well as in vivo activity against T. gondii. Although some variation of the activity of the com- pound against different strains of T. gondii was observed, a concentration of 4.8 x 10' M was sufficient to inhibit intracellular replication of tachyzoites from six of the seven strains examined in this study. For some strains, a concentration as low as 4.8 x 10-9 M (1.7 ng/ml) was inhibitory for in vitro replication of tachyzoites. As expected, the concentration necessary for killing bradyzoites within cysts was higher than for tachyzoites. Besides being protected from external agents by the relatively thick cyst membrane, bradyzoites may be relatively dormant metabolically, which would make them more resistant to drugs which act on metabolic pathways. In this context, it has been reported that morphological changes observed by light and electron microscopy occurred in replicating organisms within cysts, within the cyst wall, and in bradyzoites of cysts obtained from chronically infected mice treated with sulfamethoxypyrazine-pyrimethamine (28) . The degree of damage was observed to be proportional to the intensity of metabolism ("metabolism" was not defined). Small cysts with dividing, "metabolically active" bradyzoites showed damage, whereas large, "metabolically dormant" cysts were not affected (28) . The mechanism of action of 566C80 against toxoplasmas has not been determined yet. However, antiprotozoal hydroxynaphthoquinones appear to interfere with the electron transport pathway by acting as analogs of ubiquinone (11) . sented by a delay in the time of death, was observed. In the Ly for 30 days experiment for determining activity against the cyst form in of the mice vivo, the mildly virulent strain ME49 was used. In this case, protection against death was achieved when the treatment was initiated as late as 6 weeks after the mice had been infected. Thus, mice begun on treatment with 100 mg of 566C80 per kg per day 6 weeks following infection and e COWNXOL continued on treatment for 8 weeks did not die. In contrast, 0 TREATED untreated controls began dying 6 weeks after infection, and all were dead by week 13. Our results concerning the levels of the drug in serum suggest that more frequent administration of 566C80 may be even more effective.
An important observation in this study was that treatment resulted in a steady decline in the number of T. gondii cysts in the brains of the chronically infected mice. There are reports in the literature suggesting that prolonged treatment with the pyrimethamine-sulfonamide combination may result in a reduction of the number of cysts in the brains of chronically infected mice (9, 26, 27) . However, because of the variation in the reported observations, the general consensus is that tissue cysts of T. gondii are resistant to killing iTMENT by the pyrimethamine-sulfonamide combination (6, 8) or by ie cysts of T.
other drugs used either alone or in combinations. Although mg/kg/day was the opinions of scientists and clinicians regarding the antiwas continued cyst activities of various drugs for the treatment of T. gondii times, and the may vary (6, 9, 26, 27) , most agree that the cyst form is the r initiation of most important of the stages of the life cycle of the parasite terminated. At in regard to the pathogenesis of toxoplasmosis in immunord deviation of compromised individuals, particularly in regard to the develrepresents the opment of toxoplasmic encephalitis (7, 8, 13 
